메뉴 건너뛰기




Volumn 32, Issue 12, 2012, Pages 945-951

Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: Approaches to narrow the gaps between preclinical safety evaluation and clinical outcome

Author keywords

Cardiac toxicity; Echocardiography; Isolated perfused heart; Myocyte; Therapeutic index; Tyrosine kinase inhibitor

Indexed keywords

DRUG METABOLITE; IMATINIB; NILOTINIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SIM 010603; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

EID: 84868119568     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2813     Document Type: Article
Times cited : (45)

References (51)
  • 2
    • 84866008200 scopus 로고    scopus 로고
    • Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function
    • 2011. doi: 10.1111/j.1755-5922.2011.00278.x. [Epub ahead of print]
    • Blasi E, Heyen J, Patyna S, Hemkens M, Ramirez D, John-Baptiste A, Steidl-Nichols J, McHarg A. 2011. Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function. Cardiovasc. Ther. 2011. doi: 10.1111/j.1755-5922.2011.00278.x. [Epub ahead of print]
    • (2011) Cardiovasc. Ther.
    • Blasi, E.1    Heyen, J.2    Patyna, S.3    Hemkens, M.4    Ramirez, D.5    John-Baptiste, A.6    Steidl-Nichols, J.7    McHarg, A.8
  • 4
    • 50949132320 scopus 로고    scopus 로고
    • Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics
    • Chen M, Kerkelä R, Force T. 2008. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 117: 84-95.
    • (2008) Circulation , vol.117 , pp. 84-95
    • Chen, M.1    Kerkelä, R.2    Force, T.3
  • 5
    • 74049125665 scopus 로고    scopus 로고
    • Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics
    • Cheng H, Force T. 2010. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ. Res. 106: 21-34.
    • (2010) Circ. Res. , vol.106 , pp. 21-34
    • Cheng, H.1    Force, T.2
  • 9
    • 74549192747 scopus 로고    scopus 로고
    • The Langendorff Heart
    • Dhein S, Delmar M, Mohr FW (eds). Springer Berlin Heidelberg: New York. Part 2,2
    • Dhein S. 2005. The Langendorff Heart. In Practical Methods in Cardiovascular Research, Dhein S, Delmar M, Mohr FW (eds). Springer Berlin Heidelberg: New York. Part 2, 2, 155-172.
    • (2005) Practical Methods in Cardiovascular Research , pp. 155-172
    • Dhein, S.1
  • 11
    • 34247480545 scopus 로고    scopus 로고
    • Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
    • Force T, Krause DS, Van Etten RA. 2007. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7: 332-344.
    • (2007) Nat. Rev. Cancer , vol.7 , pp. 332-344
    • Force, T.1    Krause, D.S.2    Van Etten, R.A.3
  • 13
    • 33749003166 scopus 로고    scopus 로고
    • Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction
    • Gelb BD, Tartaglia M. 2006. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum. Mol. Genet. 15: R220-R226.
    • (2006) Hum. Mol. Genet. , vol.15
    • Gelb, B.D.1    Tartaglia, M.2
  • 14
    • 25444484658 scopus 로고    scopus 로고
    • Imatinib for the treatment of pulmonary arterial hypertension
    • Ghofrani HA, Seeger W, Grimminger F. 2005. Imatinib for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 353: 1412-1413.
    • (2005) N. Engl. J. Med. , vol.353 , pp. 1412-1413
    • Ghofrani, H.A.1    Seeger, W.2    Grimminger, F.3
  • 15
    • 84855246295 scopus 로고    scopus 로고
    • Human stem cell-derived cardiomyocytes for pharmacological and toxicological modeling
    • Harding SE. 2011. Human stem cell-derived cardiomyocytes for pharmacological and toxicological modeling. Ann. N. Y. Acad. Sci. 1245: 48-49.
    • (2011) Ann. N. Y. Acad. Sci. , vol.1245 , pp. 48-49
    • Harding, S.E.1
  • 16
    • 77950042300 scopus 로고    scopus 로고
    • The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity
    • Hasinoff BB. 2010. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol. Appl. Pharmacol. 244: 190-195.
    • (2010) Toxicol. Appl. Pharmacol. , vol.244 , pp. 190-195
    • Hasinoff, B.B.1
  • 17
    • 57349174523 scopus 로고    scopus 로고
    • Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib
    • Hasinoff BB, Patel D, O'Hara KA. 2008. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol. Pharmacol. 74: 1722-1728.
    • (2008) Mol. Pharmacol. , vol.74 , pp. 1722-1728
    • Hasinoff, B.B.1    Patel, D.2    O'Hara, K.A.3
  • 19
    • 0036213057 scopus 로고    scopus 로고
    • Mixed signals in heart failure: cancer rules
    • Hoshijima M, Chien KR. 2002. Mixed signals in heart failure: cancer rules. J. Clin. Invest. 109: 849-855.
    • (2002) J. Clin. Invest. , vol.109 , pp. 849-855
    • Hoshijima, M.1    Chien, K.R.2
  • 20
    • 84865760057 scopus 로고    scopus 로고
    • Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase
    • doi: 10.1093/toxsci/kfs192, published online on May 28, 2012.
    • Hu W, Lu S, Mcalpine I, Jamieson J, Lee D, Marroquin L, Heyen J, Jessen BA. 2012. Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase. Toxicol. Sci. doi: 10.1093/toxsci/kfs192, published online on May 28, 2012.
    • (2012) Toxicol. Sci.
    • Hu, W.1    Lu, S.2    Mcalpine, I.3    Jamieson, J.4    Lee, D.5    Marroquin, L.6    Heyen, J.7    Jessen, B.A.8
  • 21
    • 84875927801 scopus 로고    scopus 로고
    • ICH S7A.Safety Pharmacology Studies for Human Pharmaceuticals [WWW document]. URL(accessed 18 July 2012)
    • ICH S7A. 2000. Safety Pharmacology Studies for Human Pharmaceuticals [WWW document]. URL http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf (accessed 18 July 2012).
    • (2000)
  • 22
    • 84875938989 scopus 로고    scopus 로고
    • ICH S7B. Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals [WWW document]. URL(accessed 18 July 2012)
    • ICH S7B. 2005. Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals [WWW document]. URL http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf (accessed 18 July 2012).
    • (2005)
  • 23
    • 84875921546 scopus 로고    scopus 로고
    • ICH S9. Nonclinical Evaluation for Anticancer Pharmaceuticals [WWW document]. URL(accessed 18 July 2012)
    • ICH S9. 2009. Nonclinical Evaluation for Anticancer Pharmaceuticals [WWW document]. URL http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S9/Step4/S9_Step4_Guideline.pdf (accessed 18 July 2012).
    • (2009)
  • 24
    • 77957231200 scopus 로고    scopus 로고
    • Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels
    • Kappers MHW, van Esch JHM, Sluiter W, Sleijfer S, Danser AHJ, van den Meiracker AH. 2010. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56: 675-681.
    • (2010) Hypertension , vol.56 , pp. 675-681
    • Kappers, M.H.W.1    van Esch, J.H.M.2    Sluiter, W.3    Sleijfer, S.4    Danser, A.H.J.5    van den Meiracker, A.H.6
  • 29
    • 77955435768 scopus 로고    scopus 로고
    • The new high- sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes
    • Lindahl B, Venge P, James S. 2010. The new high- sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes. Am. Heart J. 160: 224-229.
    • (2010) Am. Heart J. , vol.160 , pp. 224-229
    • Lindahl, B.1    Venge, P.2    James, S.3
  • 30
    • 73949151268 scopus 로고    scopus 로고
    • Echocardiographic examination in rats and mice
    • Liu J, Rigel DF. 2009. Echocardiographic examination in rats and mice. Methods Mol. Biol. 573: 139-155.
    • (2009) Methods Mol. Biol. , vol.573 , pp. 139-155
    • Liu, J.1    Rigel, D.F.2
  • 31
    • 84862798153 scopus 로고    scopus 로고
    • Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs
    • Mao Y, Xia Z, Zhang X, Zong Y, Zhu L, Yuan B, Lu C. 2012. Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs. Food Chem. Tox. 50: 1256-1270.
    • (2012) Food Chem. Tox. , vol.50 , pp. 1256-1270
    • Mao, Y.1    Xia, Z.2    Zhang, X.3    Zong, Y.4    Zhu, L.5    Yuan, B.6    Lu, C.7
  • 32
    • 84868156647 scopus 로고    scopus 로고
    • Cardiovascular events (CVEs) associated with tyrosine kinase inhibitor (TKI) therapy in patients with metastatic renal cell carcinoma (mRCC) at a regional cancer center
    • abstr e16040
    • McGhie J, Mackenzie MJ, Winquist E, Ernst S, Sax L, O'Brien P. 2009. Cardiovascular events (CVEs) associated with tyrosine kinase inhibitor (TKI) therapy in patients with metastatic renal cell carcinoma (mRCC) at a regional cancer center. J. Clin. Oncol. 27(suppl): abstr e16040.
    • (2009) J. Clin. Oncol. , vol.27 , Issue.SUPPL
    • McGhie, J.1    Mackenzie, M.J.2    Winquist, E.3    Ernst, S.4    Sax, L.5    O'Brien, P.6
  • 33
    • 77956045289 scopus 로고    scopus 로고
    • Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys
    • McMahon C, Mitchell AZ, Klein JL, Jenkins AC, Sarazan RD. 2010. Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys. J. Pharmacol. Toxicol. Methods 62: 127-135.
    • (2010) J. Pharmacol. Toxicol. Methods , vol.62 , pp. 127-135
    • McMahon, C.1    Mitchell, A.Z.2    Klein, J.L.3    Jenkins, A.C.4    Sarazan, R.D.5
  • 34
  • 35
    • 84868121468 scopus 로고    scopus 로고
    • The Working Heart
    • Dhein S, Delmar M, Mohr FW (eds). Springer Berlin Heidelberg: New York. Part 2, 2
    • Merx M, Schrader J. 2005. The Working Heart. In Practical Methods in Cardiovascular Research, Dhein S, Delmar M, Mohr FW (eds). Springer Berlin Heidelberg: New York. Part 2, 2, 173-189.
    • (2005) Practical Methods in Cardiovascular Research , pp. 173-189
    • Merx, M.1    Schrader, J.2
  • 36
    • 0018186901 scopus 로고
    • Evidence for non-infiltrative cardiomyopathy in acute leukaemia and lymphoma. A clinical and echocardiographic study
    • Mir MA. 1978. Evidence for non-infiltrative cardiomyopathy in acute leukaemia and lymphoma. A clinical and echocardiographic study. Br. Heart J. 40: 725-733.
    • (1978) Br. Heart J. , vol.40 , pp. 725-733
    • Mir, M.A.1
  • 38
    • 84875935014 scopus 로고    scopus 로고
    • Nilotinib.EMA Scientific Discussion [WWW document]. URL(accessed 18 July 2012)
    • Nilotinib. 2007. EMA Scientific Discussion [WWW document]. URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000798/WC500034398.pdf (accessed 18 July 2012).
    • (2007)
  • 39
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen SE, Wolski K. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356: 2457-2471.
    • (2007) N. Engl. J. Med. , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 40
    • 70350072838 scopus 로고    scopus 로고
    • Cardiotoxicity induced by tyrosine kinase inhibitors
    • Orphanos GS, Ioannidis GN, Ardavanis AG. 2009. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 48: 964-970.
    • (2009) Acta Oncol. , vol.48 , pp. 964-970
    • Orphanos, G.S.1    Ioannidis, G.N.2    Ardavanis, A.G.3
  • 42
    • 31344456635 scopus 로고    scopus 로고
    • The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors
    • Peterson JT. 2006. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69: 677-687.
    • (2006) Cardiovasc. Res. , vol.69 , pp. 677-687
    • Peterson, J.T.1
  • 47
    • 84875926514 scopus 로고    scopus 로고
    • Sutent.FDA NDA Pharmacology Review [WWW document]. URL(accessed 18 July 2012)
    • Sutent. 2006. FDA NDA Pharmacology Review [WWW document]. URL http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_S000_Sutent_PharmR.pdf (accessed 18 July 2012).
    • (2006)
  • 48
    • 84875962881 scopus 로고    scopus 로고
    • SUTENT®(sunitinib malate). The FDA Approved Label [WWW document]. URL (or United States Product Information 2011) (accessed 18 July 2012)
    • SUTENT® (sunitinib malate). 2011. The FDA Approved Label [WWW document]. URL http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf (or United States Product Information 2011) (accessed 18 July 2012).
    • (2011)
  • 49
    • 84875959741 scopus 로고    scopus 로고
    • VOTRIENT®Data sheet of New Zealand "Medsafe" [WWW document]. URL(accessed 18 July 2012)
    • VOTRIENT®. 2012. Data sheet of New Zealand "Medsafe" [WWW document]. URL http://www.medsafe.govt.nz/profs/datasheet/v/votrienttab.pdf (accessed 18 July 2012).
    • (2012)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.